Gracell Biotechnologies Inc. (GRCL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gracell Biotechnologies Inc. (GRCL) has a cash flow conversion efficiency ratio of -0.029x as of March 2021. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-63.95 Million) by net assets ($2.19 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View Gracell Biotechnologies Inc. stock price for real-time trading data and today's change.
Gracell Biotechnologies Inc. - Cash Flow Conversion Efficiency Trend (2018–2022)
This chart illustrates how Gracell Biotechnologies Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Gracell Biotechnologies Inc. market cap and net worth for the company's overall valuation and market capitalisation.
Gracell Biotechnologies Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gracell Biotechnologies Inc. ranked by their cash flow conversion efficiency. Also see GRCL total asset value for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
-0.077x |
|
SK Networks Co Ltd
KO:001740
|
0.165x |
|
Ategrity Specialty Insurance Company Holdings
NYSE:ASIC
|
0.066x |
|
Sinostone Guangdong Co Ltd
SHE:001212
|
0.011x |
|
HyUnion Holding Co Ltd
SHE:002537
|
0.017x |
|
Shenzhen United Winners Laser Co Ltd
SHG:688518
|
0.024x |
|
Fugro N.V.
AS:FUR
|
0.023x |
|
TWO HARBORS INV. DL-0001
F:2H2
|
0.066x |
Annual Cash Flow Conversion Efficiency for Gracell Biotechnologies Inc. (2018–2022)
The table below shows the annual cash flow conversion efficiency of Gracell Biotechnologies Inc. from 2018 to 2022. Review how financially flexible is Gracell Biotechnologies Inc. to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $1.38 Billion | $-3.31 Billion | -2.404x | -1342.35% |
| 2021-12-31 | $1.83 Billion | $-304.55 Million | -0.167x | +31.06% |
| 2020-12-31 | $819.66 Million | $-198.15 Million | -0.242x | +54.41% |
| 2019-12-31 | $255.36 Million | $-135.39 Million | -0.530x | +97.96% |
| 2018-12-31 | $2.38 Million | $-61.86 Million | -25.957x | -- |
About Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enable… Read more